- Home
- TBNK vs ALXO Comparison
TBNK vs ALXO Comparison
Compare TBNK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBNK
- ALXO
- Stock Information
- Founded
- TBNK 1921
- ALXO 2015
- Country
- TBNK United States
- ALXO United States
- Employees
- TBNK N/A
- ALXO N/A
- Industry
- TBNK Savings Institutions
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- TBNK Finance
- ALXO Health Care
- Exchange
- TBNK Nasdaq
- ALXO Nasdaq
- Market Cap
- TBNK 65.7M
- ALXO 76.5M
- IPO Year
- TBNK N/A
- ALXO 2020
- Fundamental
- Price
- TBNK $8.37
- ALXO $0.66
- Analyst Decision
- TBNK Hold
- ALXO Strong Buy
- Analyst Count
- TBNK 2
- ALXO 6
- Target Price
- TBNK $9.89
- ALXO $4.14
- AVG Volume (30 Days)
- TBNK 12.8K
- ALXO 1.4M
- Earning Date
- TBNK 05-02-2025
- ALXO 03-06-2025
- Dividend Yield
- TBNK 0.48%
- ALXO N/A
- EPS Growth
- TBNK N/A
- ALXO N/A
- EPS
- TBNK N/A
- ALXO N/A
- Revenue
- TBNK $36,403,000.00
- ALXO N/A
- Revenue This Year
- TBNK $5.07
- ALXO N/A
- Revenue Next Year
- TBNK $14.93
- ALXO N/A
- P/E Ratio
- TBNK N/A
- ALXO N/A
- Revenue Growth
- TBNK N/A
- ALXO N/A
- 52 Week Low
- TBNK $6.92
- ALXO $0.65
- 52 Week High
- TBNK $11.44
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- TBNK 47.96
- ALXO 33.23
- Support Level
- TBNK $8.11
- ALXO $0.65
- Resistance Level
- TBNK $8.62
- ALXO $0.74
- Average True Range (ATR)
- TBNK 0.20
- ALXO 0.07
- MACD
- TBNK 0.04
- ALXO -0.00
- Stochastic Oscillator
- TBNK 55.74
- ALXO 0.54
About TBNK Territorial Bancorp Inc.
Territorial Bancorp Inc operates as a bank holding company. It offers a wide variety of FDIC-insured deposit products and loan products for the consumer and small businesses. Its business consists of accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in one-to-four-family residential mortgage loans and investment securities. The company offers a variety of deposit accounts, including passbook and statement savings accounts, certificates of deposit, money market accounts, commercial and regular checking accounts and Super NOW accounts Its loan segment portfolio consists of Residential Mortgage; Construction, Commercial, and Other Mortgage Loans; Home Equity loans & line of credit; and Consumer & others.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.